Introduction {#sec1-0300060516662404}
============

Crohn's disease is a type of inflammatory bowel disease associated with chronic relapsing inflammation of the digestive tract anywhere from the mouth to the anus.^[@bibr1-0300060516662404]^ Although its aetiopathogenesis remains unclear, it is well established that Crohn's disease is a complex disorder resulting from the interactions of genetic, environmental and microbial factors. Among these, genetic factors may be responsible for a major component of disease susceptibility.^[@bibr2-0300060516662404]^

The role of autophagy processes in the development of inflammatory bowel disease is attracting increasing attention.^[@bibr3-0300060516662404]^ It is possible that genes involved in the autophagy pathway may contribute to the pathogenesis of Crohn's disease. The autophagy-related 16-like 1 (*ATG16L1*) gene encodes an important protein involved in the formation of autophagosomes during autophagy.^[@bibr4-0300060516662404]^ Genome-wide association studies have shown an association between *ATG16L1* polymorphism involving an amino acid change at position 300 and increased susceptibility to Crohn's disease.^[@bibr5-0300060516662404],[@bibr6-0300060516662404]^ This substitution of threonine with alanine is the result of a single nucleotide polymorphism in which adenine (A) is replaced with guanine (G). This association has been examined in numerous studies, but the results have been inconsistent. The present meta-analysis was designed to evaluate the association between *ATG16L1* and Crohn's disease using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria.^[@bibr7-0300060516662404]^

Materials and methods {#sec2-0300060516662404}
=====================

Literature search {#sec3-0300060516662404}
-----------------

Two investigators (B.B.Z and B.Y.) systematically searched the databases PubMed (up to June 2016), Embase (1966 to June 2016) and Web of Science (2003 to June 2016), and also references from articles, reviews and abstracts presented at meetings of related scientific societies. The following search terms were used: ("*ATG16L1*") AND ("Crohn's disease" OR "inflammatory bowel diseases") AND ("polymorphism" OR "mutation" OR "variant" OR "genotype"). Studies were limited to those published in English.

Inclusion criteria and quality assessment {#sec4-0300060516662404}
-----------------------------------------

The same two investigators independently screened each of the titles, abstracts and full texts to determine whether the studies met the following criteria: (i) evaluation of the association of Crohn's disease and *ATG16L1* polymorphism; (ii) case--control design; (iii) sufficient data for the estimation of odds ratios (ORs) and 95% confidence intervals (CIs). In addition, a quality assessment was performed on all included studies using the Newcastle--Ottawa Scale (NOS) as described elsewhere.^[@bibr8-0300060516662404]^

Data extraction {#sec5-0300060516662404}
---------------

The following data were collected from each study included in the meta-analysis: first author's name, publication date, country, total numbers of cases and controls, and frequency of *ATG16L1* genotypes in cases and controls.

Statistical analyses {#sec6-0300060516662404}
--------------------

Strength of agreement between the investigators regarding study selection was evaluated using the Kappa statistic. The combined ORs and 95% CIs were calculated for the allelic model (G allele versus A allele), the additive model (GG versus AA), the dominant model (GA + GG versus AA) and the recessive model (GG versus GA + AA) using either the random effects model^[@bibr9-0300060516662404]^ or the fixed effects model.^[@bibr10-0300060516662404]^ Galbraith plots were created to graphically assess the source of any heterogeneity. Publication bias was analyzed using Begg's funnel plots and Egger's test, with a *P*-value \< 0.05 being considered representative of statistically significant publication bias.^[@bibr11-0300060516662404]^ Conformity with the Hardy--Weinberg equilibrium amongst the controls was determined using the χ^2^-square test and was considered to be in agreement when the *P*-value is ≥ 0.05. All statistical analyses were performed using Stata statistical software version 11.0 (StataCorp, College Station, TX, USA).

Results {#sec7-0300060516662404}
=======

Study characteristics {#sec8-0300060516662404}
---------------------

A total of 843 potentially relevant articles were initially identified. After exclusion of duplicate studies and application of the inclusion criteria, a total of 44 articles^[@bibr12-0300060516662404][@bibr13-0300060516662404][@bibr14-0300060516662404][@bibr15-0300060516662404][@bibr16-0300060516662404][@bibr17-0300060516662404][@bibr18-0300060516662404][@bibr19-0300060516662404][@bibr20-0300060516662404][@bibr21-0300060516662404][@bibr22-0300060516662404][@bibr23-0300060516662404][@bibr24-0300060516662404][@bibr25-0300060516662404][@bibr26-0300060516662404][@bibr27-0300060516662404][@bibr28-0300060516662404][@bibr29-0300060516662404][@bibr30-0300060516662404][@bibr31-0300060516662404][@bibr32-0300060516662404][@bibr33-0300060516662404][@bibr34-0300060516662404][@bibr35-0300060516662404][@bibr36-0300060516662404][@bibr37-0300060516662404][@bibr38-0300060516662404][@bibr39-0300060516662404][@bibr40-0300060516662404][@bibr41-0300060516662404][@bibr42-0300060516662404][@bibr43-0300060516662404][@bibr44-0300060516662404][@bibr45-0300060516662404][@bibr46-0300060516662404][@bibr47-0300060516662404][@bibr48-0300060516662404][@bibr49-0300060516662404][@bibr50-0300060516662404][@bibr51-0300060516662404][@bibr52-0300060516662404][@bibr53-0300060516662404][@bibr54-0300060516662404]--[@bibr55-0300060516662404]^ were included in the qualitative synthesis ([Figure 1](#fig1-0300060516662404){ref-type="fig"}). Büning et al.^[@bibr13-0300060516662404]^ contained three separate case--control studies and Fowler et al.^[@bibr19-0300060516662404]^ contained two separate case--control studies; therefore, a total of 47 case--control studies involving 18 638 cases and 30 181 controls were included in the final meta-analysis. The main characteristics of these studies are given in [Table 1](#table1-0300060516662404){ref-type="table"}. Figure 1.Flow diagram of the study selection process. CD, Crohn's disease. Table 1.Main characteristics of studies included in the meta-analysis.ReferenceSource of subjectsGenotype and allele distribution (case/control)HWENOS scoreGGGAAAGConformsStatistical significanceBaldassano et al., 2007^[@bibr12-0300060516662404]^Population-based58/7865/13619/67181/292YesNS6Büning et al., 2007:^[@bibr13-0300060516662404]^ study 1Population-based98/68149/14363/74345/279YesNS6Büning et al., 2007:^[@bibr13-0300060516662404]^ study 2Population-based38/4986/10923/49162/207YesNS6Büning et al., 2007:^[@bibr13-0300060516662404]^ study 3Population-based60/6678/10219/47198/234YesNS6Cummings et al., 2007^[@bibr14-0300060516662404]^Hospital-based209/196282/33081/157700/722YesNS6Prescott et al., 2007^[@bibr15-0300060516662404]^Population-based435/321565/626236/2881435/1268YesNS6Roberts et al., 2007^[@bibr16-0300060516662404]^Population-based166/130243/28587/134575/545YesNS7Yamazaki et al., 2007^[@bibr17-0300060516662404]^Population-based23/32184/167274/238230/231YesNS6Baptista et al., 2008^[@bibr18-0300060516662404]^Population-based46/4294/9040/57186/174YesNS8Fowler et al., 2008:^[@bibr19-0300060516662404]^ study 1Population-based243/339315/601111/304801/1279YesNS6Fowler et al., 2008:^[@bibr19-0300060516662404]^ study 2Population-based59/11073/18922/121191/409No*P* = 0.046Gaj et al., 2008^[@bibr20-0300060516662404]^Population-based24/3225/7011/3773/134YesNS8Glas et al., 2008^[@bibr21-0300060516662404]^Population-based---------906/1673N/AN/A8Hancock et al., 2008^[@bibr22-0300060516662404]^Population-based216/321288/56982/266720/1211YesNS7Lakatos et al., 2008^[@bibr23-0300060516662404]^Population-based92/33125/8349/33309/149YesNS7Lappalainen et al., 2008^[@bibr24-0300060516662404]^Population-based---------232/179N/AN/A6Latiano et al., 2008^[@bibr25-0300060516662404]^Population-based227/214335/376105/159789/804YesNS7Okazaki et al., 2008^[@bibr26-0300060516662404]^Population-based77/88103/15028/76257/326YesNS8Perricone et al. 2008^[@bibr27-0300060516662404]^Population-based33/3073/7657/54139/136YesNS7Peterson et al., 2008^[@bibr28-0300060516662404]^Population-based---------655/505N/AN/A6Van Limbergen et al., 2008^[@bibr29-0300060516662404]^Population-based217/98294/176118/71728/372YesNS6Weersma et al., 2008^[@bibr30-0300060516662404]^Population-based121/280125/42840/163367/988YesNS7Amre et al., 2009^[@bibr31-0300060516662404]^Population-based102/64137/13547/91341/263YesNS8Dema et al., 2009^[@bibr32-0300060516662404]^Population-based178/246314/407115/206670/899YesNS7Dusatkova et al., 2009^[@bibr33-0300060516662404]^Population-based107/132158/23968/128372/503YesNS7Lacher et al., 2009^[@bibr34-0300060516662404]^Population-based60/5673/12819/69193/240YesNS7Márquez et al., 2009^[@bibr35-0300060516662404]^Population-based125/221156/34763/177406/789YesNS7Newman et al., 2009^[@bibr36-0300060516662404]^Population-based159/253204/41572/227522/921No*P* = 0.039Palomino-Morales et al., 2009^[@bibr37-0300060516662404]^Hospital-based216/183253/31675/167685/682YesNS7Cotterill et al., 2010^[@bibr38-0300060516662404]^Population-based---------317/840N/AN/A7Csöngei et al., 2010^[@bibr39-0300060516662404]^Population-based108/79151/16356/72367/321YesNS7Gazouli et al., 2010^[@bibr40-0300060516662404]^Population-based189/161222/27463/104600/596YesNS6Sventoraityte et al., 2010^[@bibr41-0300060516662404]^Population-based16/4428/8911/5360/177YesNS8Fabio et al., 2011^[@bibr42-0300060516662404]^Population-based94/50134/9751/43322/197YesNS6Frank et al., 2011^[@bibr43-0300060516662404]^Hospital-based25/1722/1914/2372/53No*P* = 0.0075Lauriola et al., 2011^[@bibr44-0300060516662404]^Population-based6/69/113/321/23YesNS6Jung et al., 2012^[@bibr45-0300060516662404]^Population-based---------638/864N/AN/A6Wang et al., 2012^[@bibr46-0300060516662404]^Population-based44/33164/140141/179252/206YesNS6Hirano et al., 2013^[@bibr47-0300060516662404]^Population-based---------1993/10141N/AN/A6Dalton et al., 2014^[@bibr48-0300060516662404]^Population-based22/849/3312/1493/49YesNS6Jakobsen et al., 2014^[@bibr49-0300060516662404]^Population-based---------293/566N/AN/A7Scolaro et al., 2014^[@bibr50-0300060516662404]^Population-based25/4853/10628/84103/202YesNS8Serbati et al., 2014^[@bibr51-0300060516662404]^Population-based10/943/7616/3063/94No*P* \< 0.0016Zhang et al., 2014^[@bibr52-0300060516662404]^Population-based77/62134/166209/272288/290No*P* \< 0.0017Na et al., 2015^[@bibr53-0300060516662404]^Population-based---------54/51N/AN/A7Salem et al., 2015^[@bibr54-0300060516662404]^Hospital-based108/2978/1350/15294/71No*P* \< 0.0016Yang et al., 2015^[@bibr55-0300060516662404]^Population-based226/211838/1033745/11921290/1455YesNS7[^1][^2]

Quantitative synthesis {#sec9-0300060516662404}
----------------------

When all the studies were pooled in the meta-analysis, a significant association was seen between *ATG16L1* and Crohn's disease in all four genetic models (allelic model: OR = 1.29, 95% CI = 1.22, 1.37, [Figure 2](#fig2-0300060516662404){ref-type="fig"}; additive model: OR = 1.80, 95% CI = 1.68, 1.92, [Figure 3](#fig3-0300060516662404){ref-type="fig"}; dominant model: OR = 1.47, 95% CI = 1.39, 1.55, [Figure 4](#fig4-0300060516662404){ref-type="fig"}; recessive model: OR = 1.46, 95% CI = 1.39, 1.54, [Figure 5](#fig5-0300060516662404){ref-type="fig"}). When stratified by study design (population- or hospital-based), a significant association between *ATG16L1* and Crohn's disease was still seen in all four genetic models ([Table 2](#table2-0300060516662404){ref-type="table"}). Figure 2.Forest plot of the association between *ATG16L1* and Crohn's disease using the allelic model (G allele versus A allele). The pooled odds ratio (OR) and 95% confidence intervals (CI) are indicated by the diamond. Percentage weights were calculated using a random effects model. Figure 3.Forest plot of the association between *ATG16L1* and Crohn's disease using the additive model (GG versus AA). The pooled odds ratio (OR) and 95% confidence intervals (CI) are indicated by the diamond. Percentage weights were calculated using a fixed effects model. Figure 4.Forest plot of the association between *ATG16L1* and Crohn's disease using the dominant model (GG + GA versus AA). The pooled odds ratio (OR) and 95% confidence intervals (CI) are indicated by the diamond. Percentage weights were calculated using a fixed effects model. Figure 5.Forest plot of the association between *ATG16L1* and Crohn's disease using the recessive model (GG versus GA + AA). The pooled odds ratio (OR) and 95% confidence intervals (CI) are indicated by the diamond. Percentage weights were calculated using a fixed effects model. Table 2.Results of meta-analysis and subgroup analysis for the association between *ATG16L1* and Crohn's disease according to the allelic, additive, dominant and recessive models.Group analysedAllelic model (G vs A)Additive model (GG vs AA)Dominant model (GG + GA vs AA)Recessive model (GG vs GA + AA)OR (95% CI)Analysis modelOR (95% CI)Analysis modelOR (95% CI)Analysis modelOR (95% CI)Analysis modelAll1.29 (1.22, 1.37)Random effects1.80 (1.68, 1.92)Fixed effects1.47 (1.39, 1.55)Fixed effects1.46 (1.39, 1.54)Fixed effectsPopulation-based1.28 (1.20, 1.37)Random effects1.76 (1.64, 1.89)Fixed effects1.44 (1.36, 1.52)Fixed effects1.46 (1.38, 1.54)Fixed effectsHospital-based1.46 (1.31, 1.62)Fixed effects2.18 (1.76, 2.70)Fixed effects1.86 (1.54, 2.26)Fixed effects1.51 (1.29, 1.76)Fixed effectsNOS score ≥ 71.33 (1.24, 1.43)Random effects1.83 (1.68, 1.99)Fixed effects1.49 (1.39, 1.59)Fixed effects1.47 (1.37, 1.57)Fixed effectsConform to HWE1.32 (1.24, 1.40)Random effects1.79 (1.67, 1.92)Fixed effects1.46 (1.38, 1.54)Fixed effects1.46 (1.38, 1.54)Fixed effects[^3]

Sensitivity analyses {#sec10-0300060516662404}
--------------------

Sensitivity analyses were conducted to determine whether modification of the inclusion criteria of the meta-analysis affected the final results. When the included studies were limited to those conforming to the Hardy--Weinberg equilibrium (*P* ≥ 0.05), the pooled ORs of these 33 studies were not materially different from those of the full meta-analysis ([Table 2](#table2-0300060516662404){ref-type="table"}). Likewise, when the included studies were limited to those with a high NOS score (≥7), the pooled ORs of these 22 studies were not materially different from those of the full meta-analysis ([Table 2](#table2-0300060516662404){ref-type="table"}).

Analysis of heterogeneity {#sec11-0300060516662404}
-------------------------

Significant heterogeneity existed in the allelic model (I^2^ = 75.4%). A Galbraith plot was created to graphically assess the source of heterogeneity ([Figure 6](#fig6-0300060516662404){ref-type="fig"}). The studies by Yamazaki et al.,^[@bibr17-0300060516662404]^ Fowler et al.^[@bibr19-0300060516662404]^ (study 1), Latiano et al.,^[@bibr25-0300060516662404]^ Amre et al.,^[@bibr31-0300060516662404]^ Lacher et al.,^[@bibr34-0300060516662404]^ Palomino-Morales et al.,^[@bibr37-0300060516662404]^ Jung et al.^[@bibr45-0300060516662404]^ and Hirano et al.^[@bibr47-0300060516662404]^ were identified as contributors to the heterogeneity. When these eight studies were excluded, the I^2^ was 0.0% and the OR (95% CI) was 1.33 (1.28, 1.37). Figure 6.Galbraith plot of the allelic model. The outliers were the studies by Yamazaki et al.,^[@bibr17-0300060516662404]^ Fowler et al.^[@bibr19-0300060516662404]^ (study 1), Latiano et al.,^[@bibr25-0300060516662404]^ Amre et al.,^[@bibr31-0300060516662404]^ Lacher et al.,^[@bibr34-0300060516662404]^ Palomino-Morales et al.,^[@bibr37-0300060516662404]^ Jung et al.^[@bibr45-0300060516662404]^ and Hirano et al.^[@bibr47-0300060516662404]^ b, effect estimate; se, standard error.

Publication bias {#sec12-0300060516662404}
----------------

The shapes of the Begg's funnel plots did not reveal any evidence of obvious asymmetry ([Figure 7](#fig7-0300060516662404){ref-type="fig"}). No statistical evidence of publication bias was found using Egger's regression test (*P* = 0.09 for the allelic model; *P* = 0.62 for the additive model; *P* = 0.08 for the dominant model; and *P* = 0.83 for the recessive model). Figure 7.Begg's funnel plots with pseudo 95% confidence limits of all studies in the meta-analysis using the four model types: (a) allelic model (G allele versus A allele); (b) additive model (GG versus AA); (c) dominant model (GG + GA versus AA); (d) recessive model (GG versus GA + AA). SE, standard error; OR, odds ratio.

Discussion {#sec13-0300060516662404}
==========

Since Hampe et al.^[@bibr5-0300060516662404]^ reported in 2007 that *ATG16L1* gene polymorphism was associated with Crohn's disease, many studies have evaluated the relationship between *ATG16L1* and the risk of Crohn's disease.^[@bibr56-0300060516662404]^ However, the results are inconsistent. As the strength of results from a single case--control study is weak due to small sample sizes, the combination of many studies in a meta-analysis has the benefit of overcoming this limitation by increasing the sample size and generating more robust results. Meta-analysis has been widely used in genetic association studies.^[@bibr57-0300060516662404],[@bibr58-0300060516662404]^ The present meta-analysis was performed to assess whether the combined evidence supports an association between *ATG16L1* and Crohn's disease.

The present meta-analysis examined *ATG16L1* gene polymorphism and its relationship with the risk of Crohn's disease based on data from 47 case--control studies involving 18 638 cases and 30 181 controls. Most of these studies reported that *ATG16L1* was associated with the risk of Crohn's disease, but not all. The results of the meta-analyses demonstrated that overall there was evidence of a significant association between *ATG16L1* gene polymorphism and Crohn's disease. This significant association remained in all four genetic models when subgroup analyses were performed based on study design (population-based or hospital-based).

When considering the potential mechanisms linking *ATG16L1* polymorphism with an increased risk of Crohn's disease, it has been shown that *ATG16L1* polymorphism impairs the autophagy processing of pathogenic bacteria and the function of intestinal Paneth cells.^[@bibr59-0300060516662404],[@bibr60-0300060516662404]^ In addition, it has been shown that *ATG16L1* polymorphism is associated with increased susceptibility to *Helicobacter pylori* infection.^[@bibr61-0300060516662404]^ In patients with Crohn's disease, it has been reported that homozygosity of the *ATG16L1* risk allele (GG) was associated with a reduced ability to clear pathosymbionts.^[@bibr62-0300060516662404]^ Paneth cells in *ATG16L1*-deficient mice have been shown to be dysfunctional and to demonstrate increased expression of pro-inflammatory cytokines.^[@bibr63-0300060516662404],[@bibr64-0300060516662404]^

When interpreting the results of this meta-analysis, a number of limitations should be acknowledged. First, it is well known that both environmental factors and individual genetic predisposition contribute to the development of Crohn's disease. Due to the lack of original data, however, potential interactions between these two types of influence has not been evaluated. Secondly, *ATG16L1* seems to exert a close functional correlation with other genes in regulating autophagy. For example, the interaction of *ATG16L1* and *NOD2* has been implicated in the pathogenesis of Crohn's disease.^[@bibr63-0300060516662404]^ Potential gene--gene interactions require further evaluation. Thirdly, the *ATG16L1* genotype has been reported to be associated with disease phenotype,^[@bibr65-0300060516662404]^ which has clinical significance. Further combined analyses are needed to clarify the association between the *ATG16L1* genotype and Crohn's disease phenotype.

In conclusion, the present meta-analysis of robust data and unbiased results demonstrated an association between *ATG16L1* genotype and the development of Crohn's disease. These findings will be helpful in understanding the aetiology of Crohn's disease and indicate that the *ATG16L1* gene might have potential as a therapeutic or diagnostic target.
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[^1]: HWE, Hardy--Weinberg equilibrium; N/A, not available; NOS, Newcastle--Ottawa scale.

[^2]: NS, not statistically significant (*P* ≥ 0.05).

[^3]: OR, odds ratio; CI, confidence intervals; NOS, Newcastle--Ottawa Scale; HWE, Hardy--Weinberg equilibrium.
